Adverse events of 2009 novel pandemic influenza (A/H1N1) vaccination : comparison with seasonal and simultaneous vaccination by MATSUSHIMA Masahiro et al.
173Kawasaki Medical Journal 36（3）：173－178，2010
Corresponding author
Masahiro Matsushima
Department of Public Health, Kawasaki Medical 
School, 577 Matsushima, Kurashiki 701-0192, Japan
Phone : 81 86 462 1111
Fax : 81 86 462 1199
E-mail : masm@med.kawasaki-m.ac.jp
Adverse events of 2009 novel pandemic influenza (A/H1N1) vaccination
- comparison with seasonal and simultaneous vaccination -
Masahiro MATSUSHIMA,   Hajime HINENOYA,   Shigeko FUSHIMI
Hironobu KATSUYAMA
Department of Public Health, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-1092, Japan
ABSTRACT  Vaccination against novel pandemic influenza (A/H1N1) is available in Japan 
since October 2009.  During the 2009－10 influenza pandemic, this vaccine was administered 
either separately or simultaneously with seasonal influenza vaccine.  In the present study, 
we investigated the adverse events associated with novel pandemic influenza vaccination, 
and compared these events with those of seasonal influenza vaccination and simultaneous 
vaccination.  We also investigated the factors associated with the incidence of adverse events. 
   Although no serious adverse events were observed in any case (total cases, 470 ; 95 
received pandemic, 134 received seasonal, and 241 received simultaneous vaccinations), some 
subjects developed local and systemic reactions.  Local reactions like erythema and swelling 
and systemic reaction like fatigue were observed.  Among the subjects who experienced local 
reactions, those who received novel pandemic vaccination showed significantly lower incidence 
of adverse events than those who received other vaccinations; among the subjects who 
experienced systemic reactions, no statistical difference was observed.
   Odds ratios influencing the incidence of adverse events were calculated according to the 
potential risk factors using multiple logistic regression analysis.  Among the subjects who 
received the novel pandemic influenza vaccination, females exhibited higher odds ratio (8.29 
times) than males.  With regard to the age groups, the odds ratios of subjects of all age groups 
were higher　(3.74－9.28 times) than that of subjects over 50 years who received simultaneous 
vaccination.  Moreover, the odds ratios of past adverse events were significantly high　(10.9－
15.9 times), regardless of the type of vaccination. 
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INTRODUCTION
   After the pandemic caused by the novel influenza 
(A/H1N1) virus in early 2009, World Health 
Organization (WHO) promoted the development 
of treatment strategies for this pandemic influenza 
since September 20091）.  Although people were 
exposed to different strains of influenza virus every 
year, no one had developed immunity to the novel 
pandemic influenza strain.  Hence, there was a 
public health demand to develop a novel pandemic 
influenza vaccine as soon as possible2）, for which 
advanced planning and evaluation of safety and 
efficacy data were essential.  Studies on this aspect 
are required because there is no conclusive data 
about the safety of the novel pandemic influenza 
vaccination.  
   Both influenza A and B viruses are important 
respiratory pathogens, and influenza has caused 
large epidemics with high mortality rate for patients 
and aged in Japan3）.  Therefore, the Ministry of 
Health, Labor and Welfare (MHLW) implemented 
vaccination programs for both seasonal influenza 
A and B vaccines4） every year.  Further, for the 
pandemic caused by novel influenza, MHLW 
administrated novel pandemic influenza vaccination 
since October 20095）.  MHLW gave priority to 
medical personnel in novel pandemic influenza 
vaccination, and also conducted simultaneous 
vaccination programs of novel pandemic vaccine 
and seasonal vaccine6）, because both vaccination 
was required to reduce the incidence and mortality 
of influenza.  It was recommended that a person 
should receive both the vaccines in different arms.
   Novel pandemic influenza vaccination was 
administered to the staff members of Kawasaki 
Medical School Hospital between October and 
November, and subsequently, seasonal influenza 
vaccination was administered separately or 
simultaneously.   We compared the adverse 
events associated with novel pandemic influenza 
vaccination and those with seasonal influenza 
vaccination. Further, we investigated the factors 
related to the incidence of adverse events.
SUBJECTS AND METHODS
Subjects
   Influenza vaccination was administered to 3,932 
subjects working at the Kawasaki Medical School 
Hospital.  The novel pandemic influenza vaccination 
was administered to around 1,700 subjects.  An 
anonymous self-administered questionnaire was 
distributed to 2,438 subjects, of which only 547 
subjects returned the completed questionnaire 
(response rate, 22.4%). 
   This study was reviewed and approved by the 
Ethical Committee on Kawasaki Medical School 
and Kawasaki Medical School Hospital.
Types of vaccines
   The novel pandemic influenza vaccine5） contained
A/California/7/2009(H1N1) virus and the seasonal 
vaccine4） was composed of A/Brisbane/59/2007 
(H1N1), A/Uruguay/716/2007(H3N2), and B/
Brisbane/60/2008 strains.  Medical staff personnel, 
including doctors and nurses, received simultaneous 
vaccinations.  Other staff members, including 
radiologists, medical technologists, and medical 
clerks were first injected with the seasonal influenza 
vaccine in October and then with the novel 
pandemic influenza vaccine in November.
Anonymous self-administered questionnaire
   A survey was conducted after vaccination using 
an anonymous self-administered questionnaire.  The 
questions were related to baseline characteristics 
such as gender, age groups and occupation; type 
of vaccine; past history, including illness, allergy, 
influenza vaccination, and adverse events due to 
past influenza vaccination; and present illness.
Definition of adverse events
   Adverse events are defined as undesirable health 
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Table 1.　Characteristics of subjects
Pandemic
(n=95)
Type of vaccine
Seasonal
(n=134)
Simultaneous
(n=241)
Gender
　　　　　male
　　　　　female
29
66
35
99
48
193
Age groups
　　　　20’s
　　　　30’s
　　　　40’s
　　　　Over 50’s
　　　　Missing
15
20
25
35
-
21
29
32
50
2
92 *
68
49
32 *
-
Occupation
　　　　Doctor
　　　　Nurse
　　　　Others
　　　　Missing
6
4
81
4
　1
　7
110
16
58 *
162 *
7 *
14
Data are number.
In gender, there was no difference in each type of vaccine.  In 
age groups, those who received simultaneous vaccination showed 
signiﬁcantly lower in 20’s and higher in over 50’s than those who 
received other vaccinations (*: P<0.01).  In occupation, those who 
received simultaneous vaccination showed signiﬁcantly higher in 
doctor and nurse and lower in others than those who received other 
vaccinations (*: P<0.01).
Table 2.　Number of local and systemic reactions in each type of 
vaccine
Pandemic
(n=95)
Type of vaccine
Seasonal
(n=134)
Simultaneous
(n=241)
Local reaction
　　　　Erythema
　　　　Swelling
　　　　Calor
　　　　Pain
　　　　Itching
20 *
14 *
8 *
5 *
3 *
61
57
33
29
20
150
118
98
56
27
Systemic reaction
　　　　Fatigue
　　　　Itching
　　　　Headache
　　　　Fever (>37.5℃)
　　　　Nausea
7
3
5
2
2
15
7
4
4
-
30
27
15
　7
　4
Data are number.
In each of local reactions, those who received novel pandemic 
vaccination showed significantly lower incidence of adverse 
events than those who received other vaccinations (*: P<0.01). In 
systemic reactions, no statistical difference was observed.
events that occur after vaccination, regardless of 
whether there is an obvious relationship between 
vaccination and adverse events.  MHLW has 
defined that the criteria of adverse events that 
occur after novel pandemic and seasonal influenza 
vaccinations include 17 clinical conditions8）.  And 
local and systemic reactions that develop after 
vaccine administration are described in the report 
of MHLW7）.  Local reactions include erythema, 
swelling, calor, pain, and itching, and systemic 
reactions include fatigue, itchiness, headache, fever 
(body temperature >37.5 ℃ ), and nausea.
Statistical analysis
   χ2 test was performed to compare the differences 
in the odds ratios of each type of vaccination.  Odds 
ratios that influence the estimated risk with 95% 
confidence intervals were calculated by multiple 
logistic regression analysis by using JMP8.0 (SAS 
Corp.).  The risks were determined by gender, age 
group, presence of past and present illness, history 
of allergy, past influenza vaccination, and adverse 
events due to past influenza vaccination.
RESULTS
   Among the 547 subjects who responded to the 
questionnaire, 470 replied with effective answers 
(85.9%).  Among the 470 subjects, 95 had received 
the novel  pandemic influenza vaccination, 
134 seasonal influenza vaccination, and 241 
(approximately 50%) simultaneous vaccination 
(Table 1).  About 75% of the subjects were 
females.  The subjects in the age groups of 20's 
and 30's mainly received simultaneous vaccination. 
Most doctors and nurses received simultaneous 
vaccination, while other medical personnel first 
received the seasonal vaccination and then the novel 
pandemic influenza vaccination.  
   The subjects did not exhibit any of the 17 clinical 
conditions defined by MHLW8） after vaccination. 
Although no serious adverse events were observed, 
some subjects developed local and systemic 
reactions (Table 2).  Many subjects complained of 
erythema and swelling (local reactions) as well as 
fatigue (systemic reaction).  Among the subjects 
who developed local reactions, those who received 
novel pandemic vaccination showed significantly 
lower incidence of adverse events than those who 
received other vaccinations; among the subjects 
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Fig. 1. Incidence of local and systemic reaction in each type of vaccine. In local reaction, incidence of adverse events in novel 
pandemic vaccine was significantly lower than other types of vaccines, but no statistical difference in systemic reaction was 
observed between each vaccine.
who developed systemic reactions, no statistical 
difference was observed (Fig. 1).    
   Odds ratios influencing the incidence of adverse 
events (any local and systemic reaction) were 
calculated according to the potential risk factors 
using multiple logistic regression analysis (Table 
3).  Among the subjects who received the novel 
pandemic influenza vaccination, females exhibited 
higher odds ratio (8.29 times) than males.  With 
regard to age groups, the odds ratios of subjects 
of each age group were higher (3.74－9.28 times) 
than that of subjects over 50 years who received 
Table 3.　Risk determinants for adverse event divided by each vaccine
Pandemic
Type of vaccine
Seasonal Simultaneous
Gender (female/male) 8.29* (1.73-58.1) 2.65 (0.96-7.63) 0.87 (0.34-2.18)
Age groups
　20’s
　30’s
　40’s
Over 50’s
0.84 (0.14 -4.54)
1.87 (0.46 -7.91)
0.23 (0.035-1.17)
reference
2.62 (0.64-12.3)
1.17 (0.36-3.83)
0.94 (0.30-2.98)
reference
6.09* (1.86-22.2)
9.28* (2.65-36.7)
3.74* (1.10-13.9)
reference
Adverse events in past influenza
vaccination (yes/no)
15.9* (4.65-70.2) 12.0* (4.09-45.3) 10.9* (4.30-33.2)
Data are odds ratio (95% confidence interval). 
Odds ratios were calculated according to the potential risk factors using multiple logistic regression analysis.  In gender, the odds ratio (female/
male) was significantly high in pandemic influenza vaccination.  In age groups, the odds ratios of all age groups were higher than that of 
subjects over 50 years who received simultaneous vaccination.  And the odds ratios of adverse events in past influenza vaccination were 
significantly high, regardless of the type of vaccination.
simultaneous vaccination.  Moreover, the odds ratios 
of past adverse events were significantly high (10.9
－15.9 times), regardless of the type of vaccination. 
DISCUSSION
   There have been several reports on the safety and 
adverse events related to novel pandemic influenza 
vaccination.  According to a report from Japan9）, 
the incidence of adverse events in October 2009 
among 20,000 staff members of national hospitals 
was as follows: non-serious events, 2%, and serious 
events, 0.03%.  However, the incidence of adverse 
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events in subjects who received novel pandemic 
influenza vaccination in Japan from October 19, 
2009 to March 9, 2010, these values have reduced 
to 0.01% for non-serious and 0.002% for serious 
events, and are consistent with the incidence of 
adverse events in subjects who received seasonal 
influenza vaccination the incidence of adverse 
events in subjects who received seasonal influenza 
vaccination in Japan10）.  Further, according to 
a report from Centers for Disease Control and 
Prevention (CDC)11）, the incidence of serious 
adverse events related to novel pandemic influenza 
vaccination was not higher than that of seasonal 
influenza vaccination.  In Israel, Grotto reported 
that the incidence of adverse events related to novel 
pandemic influenza vaccination was very less, and 
the incidence of mild and transient adverse events 
was similar to that observed in seasonal influenza 
vaccination12）.  In the present study, no serious 
adverse events were observed in novel pandemic 
influenza vaccination, and the incidence ratios 
of both local and systemic reactions were around 
20% respectively, lower than other vaccinations. 
The novel pandemic influenza vaccination was 
concluded to be safe. 
   Since the novel pandemic influenza vaccine 
is a new vaccine, clinical trials for investigating 
simultaneous vaccination of this vaccine with 
other vaccines are currently in progress.  Both the 
novel pandemic influenza vaccine and seasonal 
influenza vaccine are used as inactivated vaccines in 
Japan4-7）.  According to the information released by 
MHLW on October 19, 2009, the abovementioned 
vaccines are safe and simultaneous vaccination 
of these vaccines is permitted6）.  Moreover, the 
Strategic Advisory Group of Experts (SAGE) on 
Immunization of WHO found no evidence that 
indicated increase in risk of adverse events due 
to simultaneous vaccination13）.  Recently, in their 
randomized examination of 355 healthy adults 
and elderly patients, Vajo et al. reported that both 
novel pandemic influenza vaccination alone and 
simultaneous vaccination were associated with few 
adverse events14）.  In the present study, simultaneous 
vaccination did not show serious or non-serious 
adverse events.  Further, no statistical difference 
was observed between seasonal and simultaneous 
vaccination in both local and systemic reactions. 
Thus, simultaneous vaccination also appeared safe.
   About the factor associated with adverse events 
in seasonal influenza vaccination, the following 
factors are associated with local and systemic 
reaction, such as gender, age, and past influenza 
vaccination15, 16）.  In the present study, gender in 
novel pandemic influenza vaccination and age 
groups in simultaneous vaccination are associated 
with adverse events.  However, multiple logistic 
regression analysis revealed that past influenza 
vaccination was not related to adverse events but 
adverse events in past influenza vaccination had 
high odds ratios in all types of vaccinations.  This 
result indicated that the adverse events were related 
to the adverse events in past influenza vaccination.
   Our study had several limitations.  First, this 
was a questionnaire-based study and participants 
in this study were voluntary; the response rate 
was also very low.  Second, when adverse events 
were observed in simultaneous vaccination, it was 
unknown which vaccine was affected to adverse 
event.  In spite of these shortcomings and small 
sample size, we clarified the safety of novel 
pandemic influenza vaccination and simultaneous 
vaccination in this study.  Further studies are 
required to confirm the adverse events on a large 
scale. 
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